AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3707815
Drug: Intraduodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraduodenal infusion of acyclovir (400 mg in 500 ml of 5% dextrose solution over 4 h)
Trial: 3707815
Drug: Sipping acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sipping acyclovir solution (same as infusion, sipped at 10.4 ml every 5 min for 4 h)
Trial: 3707815
Drug: Intraduodenal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraduodenal infusion of acyclovir (400 mg)
Trial: 3707815
Drug: Sipping acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sipping acyclovir solution
Trial: 29762363
Drug: DTaP-IPV-HB-PRP-T vaccine
RxNorm normalized name: Haemophilus influenzae type b, capsular polysaccharide inactivated tetanus toxoid conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP-IPV-HB-PRP-T vaccine (group 1)
Trial: 17662090
Drug: L-Citrulline (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Citrulline (3 g bid)
Trial: 16380708
Drug: Sibutramine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (10 mg daily for 6 months)
Trial: 12747281
Drug: Rofecoxib 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 500 mg
Trial: 8821514
Drug: Nifedipine extended
RxNorm normalized name: Nifedipine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine extended release capsule (Aprical retard)
Trial: 8821514
Drug: Standard retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard retard tablet
Trial: 1483293
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose (75 g) + pyridostigmine (120 mg)
Trial: 1483293
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + pyridostigmine (120 mg)
Trial: 1483293
Drug: Pyridostigmine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (120 mg) alone
Trial: 2990708
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (cyclophosphamide, vincristine, semustine)
Trial: 2990708
Drug: Standard-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose chemotherapy (cyclophosphamide, vincristine, semustine)
Trial: 2990708
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (cyclophosphamide, vincristine, semustine) in patients with extensive disease
Trial: 2990708
Drug: Standard-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose chemotherapy (cyclophosphamide, vincristine, semustine) in patients with extensive disease
Trial: 29782217
Drug: Dupilumab 200
RxNorm normalized name: dupilumab 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 200 mg every 2 weeks in patients with eosinophil count ≥300/mm³
Trial: 22412837
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg/day for 14 days)
Trial: 22412837
Drug: Prednisone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (40 mg/day for 4 days)
Trial: 12647845
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of insulin lispro before the afternoon meal
Trial: 26547499
Drug: Ledipasvir/Sofosbuvir (once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir/Sofosbuvir (once-daily dosage)
Trial: 24556911
Drug: Intravenous L‐alanyl‐L‐glutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L‐alanyl‐L‐glutamine dipeptide supplementation (0.5 g/kg body weight/day) for 5 days
Trial: 21778673
Drug: Menatetrenone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menatetrenone (45 mg daily) and risedronate sodium (once weekly)
Trial: 21778673
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and risedronate sodium (once weekly)
Trial: 16400468
Drug: Gabexate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate (300 mg continuous intravenous infusion in 500 mL Ringer's solution at 111 mL/h for 4.5 hours)
Trial: 11268223
Drug: Garlic preparations
RxNorm normalized name: garlic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Garlic preparations
Trial: 8335855
Drug: Heated moisturized
RxNorm normalized name: HEAT/MOISTURE EXCHANGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heated moisturized air (delivered at 40 L/min and 43 degrees C)
Trial: 31190822
Drug: 20-Hz rTMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-Hz rTMS treatment for 4 weeks
Trial: 21461716
Drug: Balneotherapy (21
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balneotherapy (21 patients) - 2 thermomineral water baths daily for 2 weeks
Trial: 21461716
Drug: Control (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (24 patients) - continued medical treatment and routine daily life
Trial: 16626957
Drug: Soy with
RxNorm normalized name: pediatric nutrition, soy with iron, lactose free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy with trace isoflavones (<4 mg)
Trial: 16626957
Drug: Soy with
RxNorm normalized name: pediatric nutrition, soy with iron, lactose free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy with 107 mg of total aglycone units of isoflavones
Trial: 17516694
Drug: Oxybutynin XL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin XL 10 mg/day
Trial: 17516694
Drug: Tolterodine IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine IR 4 mg/day
Trial: 11068350
Drug: Orthodox medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthodox medicine
Trial: 11068350
Drug: Complementary medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary medicine users
Trial: 11068350
Drug: Non-complementary medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-complementary medicine users
Trial: 8943602
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia with propofol and sufentanil (group A)
Trial: 6384848
Drug: butoconazole nitrate
RxNorm normalized name: Butoconazole Nitrate
DrugBank: Butoconazole (DB00639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: butoconazole nitrate cream 2%
Trial: 6384848
Drug: clotrimazole vaginal
RxNorm normalized name: Clotrimazole Vaginal Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clotrimazole vaginal tablets 200 mg/day
Trial: 25475929
Drug: Teneligliptin 20mg
RxNorm normalized name: teneligliptin
DrugBank: Teneligliptin (DB11950)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Teneligliptin 20mg plus metformin
Trial: 19782008
Drug: Stumvoll's early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stumvoll's early insulin secretion index in CF-NGT patients
Trial: 19782008
Drug: Insulin secretion
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin secretion rate (ISR) in CF-NGT and CFRD groups
Trial: 12706934
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg/day for four weeks)
Trial: 12706934
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg/day for four weeks)
Trial: 10921161
Drug: Yi Zhi
RxNorm normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yi Zhi Capsules (YZC)
Trial: 8769292
Drug: PEG solution
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG solution 250 ml twice a day
Trial: 6141335
Drug: gamma-vinyl GABA
RxNorm normalized name: gamma-Vinyl GABA
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gamma-vinyl GABA (3 g daily)
Trial: 22956656
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intradermal (i.d.) vaccination
Trial: 22956656
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg intramuscular (i.m.) vaccination
Trial: 22956656
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg intramuscular (i.m.) vaccination
Trial: 20119464
Drug: tapentadol IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tapentadol IR (50, 75, or 100 mg every 4 or 6 hours, maximum TDD 500 mg)
Trial: 20119464
Drug: tapentadol ER
RxNorm normalized name: tapentadol Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tapentadol ER (100, 150, 200, or 250 mg bid)
Trial: 16277587
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment before 28 weeks of gestation (N = 580)
Trial: 16277587
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving periodontal treatment after delivery (N = 290)
Trial: 16277587
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment (treatment group) vs. no treatment (control group)
Trial: 16277587
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment (treatment group) vs. gingivitis risk
Trial: 9627365
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 10 mg daily added to ERT
Trial: 9627365
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (ERT) in nonsmoking women
Trial: 9627365
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy (ERT) in cigarette smokers
Trial: 3287837
Drug: Clofibric acid
RxNorm normalized name: Clofibrate
DrugBank: Clofibrate (DB00636)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofibric acid and nicotinic acid (Treatment group)
Trial: 31166679
Drug: Ribociclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib plus endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen)
Trial: 31166679
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus endocrine therapy (goserelin and either a nonsteroidal aromatase inhibitor or tamoxifen)
Trial: 31166679
Drug: Ribociclib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib plus endocrine therapy (in subgroup of 495 patients who received an aromatase inhibitor)
Trial: 28390934
Drug: Comparator quadrivalent
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator quadrivalent inactivated influenza vaccine (IIV4)
Trial: 21245887
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no L. sporogenes supplementation)
Trial: 16476114
Drug: Glyburide tablets
RxNorm normalized name: Glyburide Tablets
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide tablets
Trial: 9058613
Drug: Local therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local therapies (intraocular injections of ganciclovir and foscarnet)
Trial: 9058613
Drug: Sustained-release ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained-release ganciclovir implant
Trial: 9058613
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of local and systemic therapies
Trial: 8132367
Drug: Fluconazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (400 mg on the first day, then 300 mg daily)
Trial: 8132367
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B (0.5 mg/kg body weight) + Flucytosine (3 x 2.5 g daily)
Trial: 25891697
Drug: Tacrolimus modified
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus modified release (TAC-MR) once daily
Trial: 25891697
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) twice daily
Trial: 9817160
Drug: Nebulized L-NAME
RxNorm normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized L-NAME (10(-1) M)
Trial: 825745
Drug: Trental 400
RxNorm normalized name: Trental 400mg Extended-Release Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trental 400 (1 tablet 3 times a day for 7 to 8 weeks)
Trial: 15132131
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 100‐mg capsules (reference)
Trial: 15132131
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 100‐mg tablets (test)
Trial: 15132131
Drug: 1 x
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 400‐mg tablet (test)
Trial: 15132131
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 100‐mg tablets versus 4 x 100‐mg capsules
Trial: 15132131
Drug: 1 x
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 400‐mg tablet versus 4 x 100‐mg capsules
Trial: 12034517
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol sequentially combined with dydrogesterone (oE2/D10)
Trial: 12034517
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol plus norethisterone acetate (tdE/NETA)
Trial: 7853047
Drug: Streptokinase treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase treatment for acute myocardial infarction
Trial: 30860570
Drug: Capivasertib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capivasertib (400 mg b.i.d. 4 days on/3 days off) with paclitaxel (90 mg/m2 on days 1, 8, and 15 of a 28-day cycle)
Trial: 30860570
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with paclitaxel (90 mg/m2 on days 1, 8, and 15 of a 28-day cycle)
Trial: 26336043
Drug: Adaptive Compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive Compression Therapy (ACT)
Trial: 23252914
Drug: Discharge-planning intervention
RxNorm normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Discharge-planning intervention combining chronic drug review, education, and enhanced transition-of-care communication
Trial: 19635148
Drug: Percutaneous transluminal
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous transluminal renal artery stenting (PTRAS) plus best medical treatment
Trial: 16636345
Drug: Exercises (pendular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercises (pendular swinging and stretching exercises 5 minutes twice a day every day)
Trial: 12468560
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 50 mg daily
Trial: 9438743
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug run-in period
Trial: 851303
Drug: High-glucose-concentration dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-glucose-concentration dialysate (717 mg/dl)
Trial: 851303
Drug: Intravenous mannitol
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous mannitol (1g/kg)
Trial: 851303
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of high-glucose-concentration dialysate and intravenous mannitol
Trial: 851303
Drug: High-glucose-concentration dialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-glucose-concentration dialysate and intravenous mannitol
Trial: 29945920
Drug: Iberdomide (0.03-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberdomide (0.03-6 mg, n=6 across seven cohorts)
Trial: 29945920
Drug: Iberdomide (0.03-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberdomide (0.03-6 mg)
Trial: 29945920
Drug: Iberdomide (0.3-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iberdomide (0.3-6 mg)
Trial: 22360996
Drug: Frequent hemodialysis
RxNorm normalized name: ferric pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Frequent hemodialysis (6 times per week daily in-center hemodialysis)
Trial: 18063446
Drug: Virosomal subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virosomal subunit influenza vaccine (vSIV, brand: Invivac)
Trial: 18063446
Drug: MF59-adjuvanted subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted subunit influenza vaccine (adSIV, brand: Fluad)
Trial: 18063446
Drug: Conventional subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional subunit influenza vaccine (SIV, brand: Influvac)
Trial: 18063446
Drug: Virosomal subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virosomal subunit influenza vaccine (vSIV)
Trial: 10527227
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (10 microg/kg)
Trial: 8669361
Drug: Conscious sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conscious sedation by means of intravenous midazolam (0.1 mg/kg)
Trial: 2045854
Drug: CMF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF chemotherapy for 12 courses
Trial: 2045854
Drug: CMF chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF chemotherapy for 8 courses followed by Adriamycin for 4 courses
Trial: 25733743
Drug: Group music
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group music therapy (n = 100)
Trial: 17133582
Drug: Pramipexole (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (median dose 0.35 mg/day)
Trial: 17133582
Drug: Placebo (median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (median dose 0.47 mg/day)
Trial: 15878754
Drug: VEGF gene
RxNorm normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VEGF gene polymorphism (BstUI C/T) in patients with oral cancer
Trial: 15878754
Drug: T/C ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T/C ratio in patients with oral cancer
Trial: 1282616
Drug: Nisoldipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (10 mg, twice daily for 21 days)
Trial: 25694481
Drug: ANG II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANG II infusion
Trial: 19940229
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of golimumab 100 mg (30‐minute infusion, n = 23)
Trial: 19940229
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of golimumab 100 mg at upper arm (n = 18)
Trial: 19940229
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of golimumab 100 mg at abdomen (n = 18)
Trial: 19940229
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of golimumab 100 mg at thigh (n = 19)
Trial: 19940229
Drug: Overall SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall SC administration of golimumab 100 mg
Trial: 19940229
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of golimumab 100 mg
Trial: 19940229
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) administration of golimumab 100 mg
Trial: 18379535
Drug: Glucose solutions
RxNorm normalized name: glucose Injectable Solution
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solutions